4/A: RA Capital Corrects Stock Option Exercise Price in Amended SEC Filing for Cidara Therapeutics

RA Capital Management files an amended Form 4 to correct an error in the reported exercise price of a stock option related to Cidara Therapeutics.

Summary

• RA Capital Management, L.P. filed an amended Form 4 with the SEC on July 22, 2024, regarding changes in beneficial ownership of Cidara Therapeutics, Inc. (CDTX) securities.
• The amendment corrects an error in the originally filed Form 4 on July 19, 2024, which incorrectly reported the exercise price of a stock option.
• The corrected filing pertains to a stock option granted on July 18, 2024, with an exercise price of $12.64.
• The option allows the holder to purchase 2,125 shares of Cidara Therapeutics common stock.
• The shares subject to the option vest on the earlier of the first anniversary of the grant date or the day prior to the Issuer's 2025 annual meeting of stockholders.
• The filing involves multiple reporting persons, including RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, all with a director and 10% owner relationship to the issuer.
• Laura Tadvalkar, a Managing Director of the Adviser, serves on the Issuer's board of directors and holds the option for the benefit of the Fund.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't contain information that would significantly impact investor sentiment, but the correction itself is a positive sign of diligence.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders.

Key Dates